Discovery of N-Isoxazolyl Biphenylsulfonamides as Potent Dual Angiotensin II and Endothelin A Receptor Antagonists
Citations Over TimeTop 16% of 2002 papers
Abstract
The ET(A) receptor antagonist (2) (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-[1,1'-biphenyl]-2-sulfonamide, BMS-193884) shares the same biphenyl core as a large number of AT(1) receptor antagonists, including irbesartan (3). Thus, it was hypothesized that merging the structural elements of 2 with those of the biphenyl AT(1) antagonists (e.g., irbesartan) would yield a compound with dual activity for both receptors. This strategy led to the design, synthesis, and discovery of (15) (4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-[1,1'-biphenyl]-2-sulfonamide, BMS-248360) as a potent and orally active dual antagonist of both AT(1) and ET(A) receptors. Compound 15 represents a new approach to treating hypertension.
Related Papers
- → Potential Hepatoprotective Effects of Irbesartan, an Accessible Angiotensin II Receptor Blocker, Against Cisplatin-Induced Liver Injury in a Rat Model(2023)4 cited
- → The pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan(2009)1 cited
- → Angiotensin Receptor Blockers in cardiovascular diseases: attention to Irbesartan(2017)1 cited
- The analysis of therapy effict about different angiotensin receptor blocker drugs on early diabetic nephropathy(2013)
- [Irbesartan--a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997].(1997)